Amuvatinib, also known as MP-470, is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity. Multitargeted receptor tyrosine kinase inhibitor MP470 binds to mutant forms of the stem cell factor receptor (c-Kit; SCFR), inhibiting clinically relevant mutants of this receptor tyrosine kinase that may be associated with resistance to therapy. In addition, MP470 inhibits activities of other receptor tyrosine kinases, such as c-Met, Ret oncoprotein, and mutant forms of Flt3 and PDGFR alpha, which are frequently dysregulated in variety of tumors.
Related Products:
Pexidartinib hcl; Pexidartinib; Telatinib; Avapritinib; Dovitinib Lactate; Linifanib; OSI-930; Crenolanib; Motesanib Diphosphate; Motesanib; Sunitinib; Imatinib mesylate; Axitinib; Masitinib; Dovitinib; ISCK03